Axil Brands vs Solesence
AXIL and SLSN side by side, both in soap, detergents, and cleaning preparations; perfumes, cosmetics, and other toilet preparations. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AXIL and SLSN compare
Solesence is the larger company, worth 3.5 times as much as Axil Brands ($119M against $33.7M).
Axil Brands grew revenue faster over the last twelve months (10.3% versus −14.0% for Solesence).
Axil Brands keeps more of each dollar of sales as profit, with a net margin of 9.3% compared with −3.8% at Solesence.
Axil Brands scores higher on the StockData Score (19 against 6 for Solesence), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AXIL | SLSN |
|---|---|---|
| Size and price | ||
| Market cap | $33.7M | $119M |
| Share price | $4.94 | $1.69 |
| Change, 1 year | 1.6% | −7.7% |
| Change, 5 years | 59.4% | −54.7% |
| Beta (5Y) | −0.22 | 3.70 |
| Employees | 13 | 115 |
| StockData Score | ||
| Total score | 19 (better) | 6 |
| Valuation score | 6 (better) | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 14.5× | – |
| P/S | 1.1× (better) | 2.2× |
| P/B | 2.5× (better) | 9.1× |
| EV/EBITDA | 8.0× | – |
| P/FCF | 7.7× | – |
| PEG | 0.30 | – |
| FCF yield | 13.0% | – |
| Fair value | $12.11 | $1.67 |
| Margin of safety | 59.2% (better) | −0.94% |
| Growth | ||
| Revenue growth (TTM) | 10.3% (better) | −14.0% |
| Revenue growth, 5Y average | 80.0% (better) | 29.4% |
| Net income growth (TTM) | 114% (better) | −134% |
| EPS growth (TTM) | 113% (better) | −143% |
| EPS growth, 5Y average | – | −7.8% |
| Profitability | ||
| Gross margin | 72.4% (better) | 26.5% |
| Operating margin | 10.0% (better) | −2.1% |
| Net margin | 9.3% (better) | −3.8% |
| FCF margin | 14.5% | – |
| Return on equity | 23.3% (better) | −15.1% |
| Return on invested capital | 43.2% (better) | −8.3% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.31 (better) | 0.97 |
| Altman Z-score | 7.41 (better) | 0.13 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.08% |
| Shareholder yield | 0.00% (better) | −0.08% |
| Ownership | ||
| Held by institutions | 15.6% | 4.5% |
| Held by insiders | 69.6% | 75.2% |
| Insider net buying, 12 months | – | $4.8K |
| Short interest, % of float | 0.48% | 2.1% |
Go deeper
- AXIL stock overview
- AXIL income statement
- AXIL valuation and score
- SLSN stock overview
- SLSN income statement
- SLSN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.